Sanofi - revenue by segment 2014-2019

In 2019, the French pharmaceutical and healthcare company by the name of Sanofi generated approximately 25.7 billion U.S. dollars through its pharmaceuticals segment. Sanofi’s relatively new consumer healthcare segment earned the company about 4.7 billion U.S. dollars in that year.

Sanofi’s top products

Sanofi develops various pharmaceutical products, including Aubagio, Lovenox, and Dupixent. In 2018 as well as 2019, the company’s top product based on revenue was Lantus. In 2019, this long-acting insulin used to treat diabetes, generated some three billion U.S. dollars. Aubagio earned the company roughly 1.89 billion U.S. dollars within the same year.

Top U.S. drugs

Based on sales numbers, Humira was by far the top prescription drug in the United States in 2018. The drug generated over 18 billion U.S. dollars in the United States that year, while Enbrel, which stood in second place, reached about 8 billion U.S. dollars. The country’s most prescribed medicines, however, were Atorvastatin, Lisinopril, and Levothyroxine. One hundred fourteen million prescriptions for Atorvastatin were dispensed in 2018.